Continuous-infusion vinblastine in refractory carcinoma of the cervix: a phase II trial.
Twenty patients with recurrent or metastatic squamous cell carcinoma of the cervix were treated with continuous-infusion vinblastine sulfate. Two patients (10%) had partial responses of 4 and 7 months' duration. Neutropenia was dose limiting. Vinblastine sulfate given by continuous infusion has limited activity in this malignancy.
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D003248:Constipation / Q000139:chemically induced; D005069:Evaluation Studies as Topic; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D014747:Vinblastine